Study on Veliparib and Topotecan for Treating Solid Tumors, Relapsed or Resistant Ovarian Cancer, or Primary Peritoneal Cancer

Inclusion Criteria

• Phase I: Adults with advanced solid tumors that cannot be surgically removed or cured with standard treatments.
• Phase II: Patients with a history of ovarian, fallopian tube, or primary peritoneal cancer.
• Must have received fewer than three previous treatments and relapsed within a year of the last platinum-based treatment.
• Must have measurable cancer that can be tracked with scans.
• Meet specific blood count and organ function requirements.
• Able to provide informed consent and willing to return for follow-up visits.
• Life expectancy of at least 12 weeks.
• Women of childbearing potential must have a negative pregnancy test and agree to use contraception.
• Able to swallow and absorb the medication.

Exclusion Criteria

• Have a standard treatment available that could cure or extend life expectancy.
• Previously treated with a PARP inhibitor or topotecan.
• Have uncontrolled illnesses or conditions that would interfere with the study.
• Have had certain treatments or therapies within a specified time before joining the study.
• Have not fully recovered from previous treatments.
• Have severe heart conditions or untreated brain metastases.
• Pregnant or nursing women, or those not willing to use contraception.
• Have other serious health conditions or active infections.
• Have another active cancer, except for certain skin or cervical cancers.
• Have had a heart attack or severe heart failure within the last six months.
• Have had more than two prior chemotherapy treatments for the current cancer.